An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran®)

Thrombosis Research

Volumn 125, Issue 4, 2010, Pages 297-302

  Magnani, H N ^a  

^a NONE   (Netherlands)

Author keywords

Danaparoid; Heparin intolerance; Post partum; Pregnancy; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; DANAPAROID; ENOXAPARIN; HEPARIN; UROKINASE; WARFARIN;

ADULT; ARTICLE; BLEEDING; BLOOD SAMPLING; BREAST MILK; CESAREAN SECTION; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDURAL ANESTHESIA; FEMALE; FETUS BLOOD; GROWTH RETARDATION; HELLP SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INJECTION SITE REACTION; INTRAUTERINE GROWTH RETARDATION; LABORATORY TEST; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL PLASMA; NEWBORN DEATH; OSTEOPOROSIS; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY TERMINATION; PRIORITY JOURNAL; SKIN NECROSIS; SPONTANEOUS ABORTION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

ABORTION, SPONTANEOUS; CHONDROITIN SULFATES; DERMATAN SULFATE; EXANTHEMA; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; PREGNANCY; RESEARCH; THROMBOSIS; TREATMENT OUTCOME;

EID: 77949567277     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.006     Document Type: Article

References (63)

1. Meuleman D.G. Orgaran (Org10172): Its pharmacological profile in experimental models. Haemost 22 (1992) 58-65
2. Ofosu F.A. Anticoagulant mechanisms od Orgaran (Org 10172) and its fraction the high affinity to antithrombin III (Org 10849). Haemost 22 (1992) 66-72
3. Chong B.H., Ismail F., Cade J., Gallus A.S., Gordon S., and Chesterman C.N. Heparin-induced thrombocytopenia: in-vitro studies with a new low molecular weight heparinoid, Org 10172. Blood 73 6 (1989) 1592-1596
4. Krauel K., Furil B., Warkentin T.E., Weitschies W., Kohlmann T., Sheppard J.A., et al. Heparin-induced thrombocytopenia - therapeutic concentrations of danaparoid unlike fondaparinux and direct thrombin inhibitors, inhibit formation of PF4/heparin complexes. J Thromb Haemost 6 (2008) 2160-2167
5. Nurmohamed M.T., Fareed J., Hoppensteadt D., Walenga J.M., and ten Cate J.W. Pharmacological and clinical strudies with Lomoparan, a low molecular weight glycosaminoglycan. Semin Thromb Hemost 17 Suppl 2 (1991) 205-213
6. Magnani H.N., and Gallus A. Heparin induced thrombocytopenia: A report of 1478 clinical outcomes of patients treated with danaparoid (Orgaran®) from 1982 to mid 2004. Thromb Haemost 95 6 (2006) 967-981
7. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D.O., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2005) 171-196
8. Lindhoff-Last E., Magnani H.N., and Kreutzenbeck H.J. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 91 3 (2005) 63-69
9. Chong B.H., and Magnani H.N. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced thrombocytopenia. 4th ed (2007), Publ Marcel Dekker Inc. 319-343
10. Adachi M., Nakatsuka M., Sasaki A., Noguchi S., et al. Effect of danaparoid on Antiphospholipid Positive Infertile Patients (2006) (English translation of an unspecified Japanese publication 2006)
11. Morikawa M., amada H., Kato E.H., Shinichiro W., Suzuki S., Sakuragi N., et al. Failure of thromboprophylaxis in pregnancy caused by dual deficiencies of Protein S and Protein C. Semin Thromb Haemost 31 3 (2005) 261-265
12. Yamamoto Y. A case of Pregnancy with Myelodysplastic Syndrome in which Thrombectomy was performed for Pulmonary Thromboembolism during pregnancy (2007) [English translation of an unspecified Japanese publication]
13. Tsutida R. A case of DVT developed in early gestation. Proc Kanto Assoc Japanese Soc Obstet Gynecol 42 3 (2005) 347
14. Boshkov L.H., Hamilton P., Lee A., and Boldt K. Successful therapy of heparin-induced thrombocytopenia with thrombosis (HITTS) in pregnancy with danaparoid sodium. Blood 94 suppl 1 (1999) 102b
15. Gerhard A., Scharf R.E., and Zotz R.B. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT). Clin Appl Thromb Hemost (Oct 7 2008) 1-4 [Electronic publication]
16. Gill J., and Kovacs M.J. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol 90 4 (1997) 648-650 [and abstract in Blood 1996;88(suppl 1) No 3053]
17. Grainger J.D., and Hay C.R.M. Heparin induced thrombocytopenia caused by danaparoid sodium. Thromb Haemost (2001) ;86(Suppl 1):Abstract 3458.
18. ®) in venous thrombosis in pregnant women with thrombophilia and heparin-induced thrombocytopemia. Thromb Haemost (2001) ;86(Suppl 1):Abstract 2997.
19. Wilhelm M.J., Schmid C., Kececioglu D., Mollhof T., Osterman H., and Scheld H.H. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 61 (1996) 920-924
20. Porzelt C., Drummer B., and Hoffmann A. Thromboprophylaxe in der Schwangerschaft nach Polytraumatisiering mit Splenektomie und Immobilisation bei heparininduzierter "relativer" Thrombozytopenie Typ II. Geburtshilfe Frauenheilkd 62 (2002) 784-786
21. Gould J., and Meyers B. Prophylactic danaparoid in heparin-induced thrombocytopenia presenting with skin manifestations in pregnancy. Blood Coagul. Fibrinolysis 13 8 (2002) A18 (Abstr P-15)
22. Schinzel H., Buhler G., Peetz D., Wiechelt J., Macciella D., and Tanner B. Die akute heparineninduzierten Thrombozytopenie Typ II während der Schwangerschaft. Intensivmedizin 43 (2006) 12-28 (duplicate of Frauenheilk 2004;64:1098-105)
23. Ducloy-Bouthors A-S, Trillot N, Depret T, Provost-Helou NEnnezat P-V et al. Conduite a tenir diagnostique devant une thrombopenie chez une patiente sous heparine pendent la grossesse, l'accouchement ou le post partum: a propos de 4 cas. 2006 pre-print
24. ®). Haemostaseologie 24 (2004) A39 [abstract P1]
25. Bergmann F. Budde U. Personal communication in ref 35.
26. Weilbach C., Rahe-Meyer N., Raymondos K., and Piepenbrock S. Delivery of a healthy child 30 weeks after resuscitation for thromboembolism and treatment with danaparoid: 5 year follow-up. J Perinat Med 34 (2006) 505-506
27. Olah Z, Schlammadinger A, Laszlo P, Razso K, Boda Z. LMWH treatment and anti-FXa monitoring of complications in pregnant women with thrombophilia. Meeting abstract obtained from The British Library.
28. Henny Ch.P., ten Cate H., ten Cate J.W., Prummel M.F., Peters M., and Buller H.R. Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid. Thromb Haemost 55 (1986) 301
29. van Besien K., Hoffman R., and Golichowski A. Pregnancy associated with lupus anticoagulant and heparin-induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res 62 (1991) 23-29
30. Greinacher A., Eckhardt T.h., Mussmann J., and Mueller-Eckhardt C. Pregnancy complicated by heparin-associated thrombocytopenia: management by a prospectively in-vitro selected heparinoid (Org 10172). Thromb Res 71 (1993) 123-126
31. Macchi L., Sarfati R., Guicheteau M., Chamberlain V., Pourrat O., Gruel Y., et al. Thromboembolic prophylaxis with danaparoid (Orgaran®) in a high thrombosis risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Clin Appl Thromb Haemost 6 4 (2000) 187-189
32. Woo Yl., Allard S., Cohen H., Letsky E., and de Swiet M. Danaparoid prophylaxis in pregnant women with heparin-induced thrombocytopenia. BJOG 109 (2002) 466-468
33. Lindhoff-Last E., and Bauersachs R. Heparin-induced Thrombocytopenia - Alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 28 (2002) 439-445
34. Schindewolf M., and Lindhoff-Last E. Alternative anticoagulation with danaparoid in two pregnancies in a patient with former heparin-induced thrombocytopenia (HIT), homozygous factor V Leiden mutation, a history of venous thrombosis and recurrent pregnancy losses. Thromb Haemost 99 (2008) 776-778
35. Harrison S.J., Rafferty I., and McColl M.D. Management of heparin allergy during pregnancy with danaparoid. Blood Coagul Fibrinolysis 12 (2001) 157-159
36. Rondeau M., Weber J.C., Haffner C., Lutun P., Nisand I., Baldauf J.T., et al. HELLP syndrome, catastrophic antiphospholipid syndrome or heparin-induced thrombocytopenia?. J Autoimmun 15 A68 (2000) [Abstract P147]
37. de Saint-Blanquat L., Simon L., Toubas M.F., and Hamza J. Traitement par le danaparoide de sodium au cours de la grossesse chez une patiente presentant une allergie cutanee aux heparines de bas poids moleculaire. Ann Fr Anesth Reanim 19 (2000) 751-754
38. Taylor A.A. Successful use of Heparinoids in a Pregnancy complicated by Allergy to Heparin. BJOG 108 (2001) 1011-1012
39. Deschamps A., Mathelier-Fusade P., and Bernaille J.L. Réaction cutanée a l'héparine pendant la grossesse: à propos d'un cas traité avec succès par le danaparoïde. Rev Fr Allergol Immunol Clin 43 (2003) 131-134
40. Bjørge L., Ernst P., and Haram K.O. Paroxysmal haemoglobinuria in pregnancy. Acta Obstet Gynaecol Scand 82 (2003) 1067-1071
41. Blickstein D., Hod M., and Bar J. Eczematous plaques related to unfractionated and low molecular weight heparin in pregnancy: cross reaction with danaparoid sodium. Blood Coagul Fibrinolysis 14 (2003) 765-768
42. Alguel G., Vormittag R., Kyrle P.A., Quehenberger P., Mannhalter C., and Pabinger I. Favourable pregnancy outcome in women with a history of venous thromboembolism and prophylactic low molecular weight heparin (LMWH). J Thromb Haemost 3 Suppl 1 (2005) [Abstr OR214]
43. Bank I., Libourel E.J., Middeldorp S., van der Meer J., and Buller H.R. High rate of skin complications due to low molecular weight heparins in pregnant women. J Thromb Haemost (2003) ;1(4):859-61.
44. Barret P., Busslères J.F., and Ferriera E. Réaction cutanée d'hypersenibilité retardée aux héparines. Quêbec Pharmacie: Pharmacovigilance vol. 55/6 (2008) 45-48
45. Mazzolai L., Hohfeld P., Spertini F., Hayoz D., Schapira M., and Duchosal M.A. Fondaparinux is a safe alternative in a case of heparin intolerance during pregnancy. Haemost Thromb Vasc Biol 108 5 (2006) 1569-1570
46. Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced Thrombocytopenia. Publ. informa healthcare 2 (2007) 21-66
47. Danhof M., de Boer A., Magnani H.N., and Stiekema J.C.J. Pharmacokinetics considerations on Orgaran (Org 10172) therapy. Haemost 22 (1992) 73-84
48. Greer I.A., and Nelson-Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thrombolism in prenancy: a systemic review of safety and efficacy. Blood 106 (2005) 401-407
49. Royal College of Obstetricians and Gynaecologists. The Investigation and Treatment of Couple with Recurrent Miscarriage. May 2003, Guideline No 17.
50. Dendrinos S., Sakkas E., and Makrakis E. Low molecular weight heparin versus intravenous immunoglobulin for recurrent abortion associated with the antiphospholipid antibody syndrome. Int J Gynaecol Obstet (Dec 28 2008) [Electronic publication]
51. Heilmann L., Schorch M., Hahn T., Adasz G., Schilberz K., Adiguzel C., et al. Pregnancy outcomes in women with antiphospholipid syndrome: report on a retrospective study. Semin Thromb Hemost 34 8 (2008) 794-802
52. Goldberg R.L., Culhane J.F., Lams J.D., and Romero R. Epidemiology and causes of pre-term birth. Lancet 371 (2008) 75-84
53. Greer I.A. Pre-eclampsia matters. BMJ 330 7491 (2005) 549-550
54. Fausett M.B., Vogtlander M., Lee R.M., Esplin M.S., Branch D.W., Rodgers G.M., et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 185 (2001) 148-152
55. Warkentin T.E. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 35 4 Suppl 5 (1998) 17-25
56. Chong B.H., Gallus A.S., Cade J.F., et al. Prospective open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost 86 (2001) 1170-1175
57. Farner B., Eichler B., Kroll H., and Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85 (2001) 950-957
58. Lubenow N., Warkentin T.E., Greinacher A., Wessel A., Sloane D.A., Krahn E.L., et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Haemost 117 (2006) 507-515
59. Grassegger A., Fritsch P., and Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid. Am Soc Dermatol Surg 27 (2001) 47-52
60. Ludwig R.J., Schindewolf M., Lindhoff-Last E., and Boehncke W.H. The influence of heparin's molelular weight and the incidence of delayed type hypersensitivity reactions revisited. Br J Dermatol (2007) 514-516
61. Figarella I., Barbaud A., Lecompte T., de Maistre E., et al. Réaction cutanée d'hypersensibilité retardée avec polisensibilisation aux héparines et héparinoides. Ann Dermatol Venereol 128 (2001) 25-30
62. Boehncke W.H., Weber L., and Gall H. Toleranz gegenüber Intravenöser Applikation von Heparin und Heparinoid bei einer Patientin mit Typ-IV Allergie auf Heparine und Heparinoide. Allergologie 19 (1996) 95
63. Gaigl Z., Pfeuffer P., Raith P., Bröcker E.B., and Trautmann A. Tolerance to intravenous heparin in patients with delayerd type hypersensitivity to heparins: a prospective study. BJH 128 (2004) 389-392